Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Nkarta, Inc. (NKTX)
Company Research
Source: GlobeNewswire
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Clinical data from our co-lead pipeline candidates have highlighted the promise of our allogeneic NK cell therapy technology to lead the next wave of cell therapy,” said Paul J. Hastings, President and CEO of Nkarta. “We believe that the future of cell therapy is improved accessibility, and NK cells may be uniquely equipped to overcome access barriers owing to their intrinsic tumor killing ability and relative ease of administration. We have shown early proof of concept that engineered NK cel
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta, Inc. (NASDAQ: NKTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $15.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Nkarta: NK Cell Therapy Advancement On Two Fronts [Seeking Alpha]Seeking Alpha
- Nkarta, Nuvation Bio, Canopy Growth among healthcare movers Mar. 25, 2024 10:00 AM ET By: Tiyashi Datta , SA News Editor [Seeking Alpha]Seeking Alpha
- Nkarta Announces Pricing of $240 Million Underwritten Offering [Yahoo! Finance]Yahoo! Finance
- Nkarta Announces Pricing of $240 Million Underwritten OfferingGlobeNewswire
NKTX
Earnings
- 3/21/24 - Beat
NKTX
Sec Filings
- 3/28/24 - Form SC
- 3/28/24 - Form SC
- 3/28/24 - Form 4
- NKTX's page on the SEC website